Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Signals

Technical Trend Overview

The stock’s technical trend has transitioned from a neutral sideways movement to a mildly bearish phase, reflecting recent price pressures. On the daily chart, moving averages have turned mildly bearish, signalling short-term weakness. The current price stands at ₹1,283.50, down 1.56% from the previous close of ₹1,303.90, with intraday trading ranging between ₹1,274.35 and ₹1,294.85.

Over the past 52 weeks, Dr Reddys Laboratories has traded between ₹1,025.90 and ₹1,377.95, indicating a relatively wide price band. The recent dip towards the lower end of this range has contributed to the cautious technical outlook.

MACD Signals: Divergent Weekly and Monthly Perspectives

The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On a weekly basis, the MACD remains bullish, suggesting that medium-term momentum retains some upward bias. However, the monthly MACD has turned mildly bearish, indicating that longer-term momentum is weakening. This divergence highlights a potential conflict between short- and long-term investor sentiment.

Such a scenario often precedes a period of consolidation or increased volatility, as market participants weigh conflicting signals before committing to a clear directional move.

RSI Remains Neutral

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently offers no definitive signal. This neutrality suggests that the stock is neither overbought nor oversold, reinforcing the view of a market in balance but vulnerable to shifts in momentum.

Investors should monitor RSI closely for any move beyond the typical 30-70 range, which could provide clearer directional cues.

Bollinger Bands Indicate Mild Bullishness

Bollinger Bands on weekly and monthly charts show a mildly bullish stance. This implies that despite recent price softness, volatility remains contained and the stock price is holding near the upper band on these timeframes. Such positioning can be interpreted as a sign of underlying strength, potentially limiting downside risk in the near term.

Moving Averages and KST: Conflicting Signals

Daily moving averages have turned mildly bearish, reflecting recent price declines and suggesting short-term selling pressure. Conversely, the Know Sure Thing (KST) indicator shows a mildly bullish signal on the weekly chart but a mildly bearish stance on the monthly chart. This split further emphasises the mixed momentum environment.

Such conflicting signals often indicate a transitional phase where the stock may experience choppy trading before establishing a clearer trend.

Volume and Dow Theory Trends

On-balance volume (OBV) and Dow Theory assessments reveal no clear trend on either weekly or monthly timeframes. The absence of volume confirmation and trend validation suggests that the current price movements lack strong conviction from market participants.

This lack of volume support may limit the sustainability of any short-term rallies or declines, underscoring the importance of monitoring volume alongside price action.

Comparative Performance Against Sensex

Dr Reddys Laboratories has outperformed the Sensex over several key periods despite recent technical softness. The stock posted a 13.2% return over the past year compared to the Sensex’s 4.35%. Over three years, the stock gained 46.45%, significantly ahead of the Sensex’s 29.7%. However, over five years, the Sensex’s 52.01% return slightly eclipsed the stock’s 44.29% gain, while the 10-year returns show the Sensex nearly doubling Dr Reddys’ performance (212.84% vs 99.38%).

Shorter-term returns also highlight resilience, with the stock up 0.98% year-to-date versus the Sensex’s decline of 8.98%, and a 0.67% gain over one month compared to the Sensex’s 7.73% fall. Even in the past week, Dr Reddys’ loss of 0.86% was less severe than the Sensex’s 3.33% drop.

Mojo Score and Rating Update

MarketsMOJO has downgraded Dr Reddys Laboratories from a Hold to a Sell rating as of 09 March 2026, reflecting the deteriorating technical outlook and subdued momentum. The current Mojo Score stands at 48.0, indicating below-average technical strength. The Market Cap Grade remains at 1, signalling a relatively low market capitalisation ranking within its sector.

This downgrade aligns with the mildly bearish technical trend and mixed indicator signals, suggesting caution for investors considering new positions.

Investor Takeaway

Dr Reddys Laboratories currently faces a technical environment characterised by mixed momentum signals and a shift towards mild bearishness. While weekly MACD and Bollinger Bands suggest some underlying strength, monthly indicators and daily moving averages point to caution. The neutral RSI and lack of volume confirmation further complicate the outlook.

Investors should weigh these technical factors alongside fundamental considerations and broader market conditions. The stock’s historical outperformance relative to the Sensex over medium-term horizons remains a positive, but the recent downgrade to a Sell rating by MarketsMOJO signals the need for prudence.

Monitoring key technical levels, particularly the 52-week low of ₹1,025.90 and the recent support zone around ₹1,274, will be critical in assessing whether the stock can stabilise or if further downside is likely.

Looking Ahead

Given the current technical landscape, Dr Reddys Laboratories may experience a period of consolidation or modest decline before a clearer trend emerges. Traders and investors should remain alert to shifts in momentum indicators and volume patterns that could herald a renewed uptrend or deeper correction.

In the meantime, diversification and consideration of alternative opportunities within the Pharmaceuticals & Biotechnology sector may be advisable, especially given the availability of peer comparisons and market-cap analyses that highlight potentially superior options.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today